行情

MRTX

MRTX

Mirati
NASDAQ

实时行情|Nasdaq Last Sale

112.25
+6.13
+5.78%
盘后: 112.25 0 0.00% 17:00 12/13 EST
开盘
106.00
昨收
106.12
最高
112.34
最低
106.00
成交量
33.12万
成交额
--
52周最高
112.34
52周最低
34.39
市值
44.27亿
市盈率(TTM)
-23.9533
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MRTX 新闻

  • BeiGene's tislelizumab combo shows positive action in ovarian cancer
  • Seeking Alpha - Article.1天前
  • BeiGene reports preliminary data on tislelizumab+sitravatinib at ESMO I-O 2019
  • Seeking Alpha - Article.1天前
  • BeiGene Highlights Data On Tislelizumab In Combo With Sitravatinib At European Society for Medical Oncology Immuno-Oncology Congress 2019
  • Benzinga.1天前
  • BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019
  • GlobeNewswire.1天前

更多

所属板块

生物技术和医学研究
+1.07%
制药与医学研究
-0.32%

热门股票

名称
价格
涨跌幅

MRTX 简况

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).
展开

Webull提供Mirati Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。